Format

Send to

Choose Destination
See comment in PubMed Commons below
BMC Med. 2013 Aug 28;11:189. doi: 10.1186/1741-7015-11-189.

Procalcitonin beyond the acute phase: novel biomediator properties?

Author information

1
Department Endocrinology, VAMC, and George Washington University School of Medicine, Washington, DC, USA. enylen@gmail.com.

Abstract

Since inflammation has been linked to carcinogenic events, discovery of relevant biomarkers may have important preventative implications. Procalcitonin (ProCT) has been shown to be an important prognostic biomarker in severe inflammatory conditions, but there is no data regarding its biomarker role, if any, beyond the acute phase. In a recent study published in BMC Medicine, Cotoi et al. analyzed whether serum ProCT levels in healthy individuals are associated with mortality outcomes. The results are affirmative in that baseline ProCT was shown to be strongly and independently associated with all-cause and cancer mortality and with the incidence of colon cancer in men. By contrast, the study indicated that high sensitivity C-reactive protein was independently associated with cardiovascular mortality but not with cancer mortality in men. Thus, baseline levels of ProCT appear to have prognostic biomarker implications potentially related to its emerging biomediator action(s).

PMID:
23984981
PMCID:
PMC3765476
DOI:
10.1186/1741-7015-11-189
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center